2024 World Conference on Lung Cancer (WCLC) - Posters-P4.11E.15 Risk Factors for Ir-AEs in Patients with NSCLC Receiving Chemotherapy Combined with a PD-1/PD-L1 Inhibitor or Nivolumab and Ipilimumab

P4.11E.15 Risk Factors for Ir-AEs in Patients with NSCLC Receiving Chemotherapy Combined with a PD-1/PD-L1 Inhibitor or Nivolumab and Ipilimumab

Back to course

Pdf Summary

The study led by Akio Nomura investigates risk factors for immune-related adverse events (ir-AEs) in patients with non-small-cell lung cancer (NSCLC) treated with chemotherapy in combination with either PD-1/PD-L1 inhibitors or nivolumab and ipilimumab. This research addresses the increased incidence of ir-AEs associated with these treatments, and while various studies have explored risk factors for such adverse events, clear determinants remain elusive for the combination with ipilimumab.<br /><br />The study retrospectively analyzed NSCLC patients receiving combined immunotherapy with or without ipilimumab across five hospitals from March 2019 to April 2022. The analysis looked into potential risk and prognostic factors for ir-AEs.<br /><br />Key findings highlight the neutrophil-to-lymphocyte ratio (NLR) of ≥5 as an independent risk factor for Grade 3 ir-AEs and a favorable prognostic factor in patients receiving ipilimumab. Conversely, C-reactive protein (CRP) levels greater than 1 were identified as independent risk factors for Grade 3 ir-AEs and poor prognostic indicators in patients not receiving ipilimumab.<br /><br />The occurrence of ir-AEs was notably higher in the ipilimumab group compared to the non-ipilimumab group. Patients with NLR ≥5 should be monitored closely for ir-AEs when receiving ipilimumab, while those with elevated CRP levels may not benefit significantly from combining chemotherapy with PD-1/PD-L1 inhibitors.<br /><br />These insights are valuable for clinicians aiming to optimize treatment strategies for NSCLC patients, tailoring therapy to minimize adverse events and improve patient outcomes. The study underscores the importance of biomarker evaluation, like NLR and CRP, in predicting treatment responses and guiding personalized therapeutic decisions in clinical practice.

Asset Subtitle

Akio Nomura

Meta Tag

Speaker Akio Nomura

Topic Metastatic NSCLC – Immunotherapy

Keywords

immune-related adverse events

non-small-cell lung cancer

PD-1/PD-L1 inhibitors

nivolumab

ipilimumab

neutrophil-to-lymphocyte ratio

C-reactive protein

biomarker evaluation

chemotherapy

personalized therapeutic decisions